Literature DB >> 31243983

Importance of Choosing Relevant Biological End Points To Predict Nanoparticle Toxicity with Computational Approaches for Human Health Risk Assessment.

Valérie Forest1, Jean-François Hochepied2,3, Jérémie Pourchez1.   

Abstract

Because it is impossible to assess in vitro or in vivo the toxicity of all nanoparticles available on the market on a case-by-case basis, computational approaches have been proposed as useful alternatives to predict in silico the hazard potential of engineered nanoparticles. Despite promising results, a major issue associated with these mathematical models lies in the a priori choice of the physicochemical descriptors and the biological end points. We performed a thorough bibliographic survey on the biological end points used for nanotoxicology purposes and compared them between experimental and computational approaches. They were found to be disparate: while conventional in vitro nanotoxicology assays usually investigate a large array of biological effects using eukaryotic cells (cytotoxicity, pro-inflammatory response, oxidative stress, genotoxicity), computational studies mostly focus on cell viability and also include studies on prokaryotic cells. We may thus wonder the relevance of building complex mathematical models able to predict accurately a biological end point if this latter is not the most relevant to support human health risk assessment. The choice of biological end points clearly deserves to be more carefully discussed. This could bridge the gap between experimental and computational nanotoxicology studies and allow in silico predictive models to reach their full potential.

Entities:  

Mesh:

Year:  2019        PMID: 31243983     DOI: 10.1021/acs.chemrestox.9b00022

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  7 in total

1.  Can an InChI for Nano Address the Need for a Simplified Representation of Complex Nanomaterials across Experimental and Nanoinformatics Studies?

Authors:  Iseult Lynch; Antreas Afantitis; Thomas Exner; Martin Himly; Vladimir Lobaskin; Philip Doganis; Dieter Maier; Natasha Sanabria; Anastasios G Papadiamantis; Anna Rybinska-Fryca; Maciej Gromelski; Tomasz Puzyn; Egon Willighagen; Blair D Johnston; Mary Gulumian; Marianne Matzke; Amaia Green Etxabe; Nathan Bossa; Angela Serra; Irene Liampa; Stacey Harper; Kaido Tämm; Alexander CØ Jensen; Pekka Kohonen; Luke Slater; Andreas Tsoumanis; Dario Greco; David A Winkler; Haralambos Sarimveis; Georgia Melagraki
Journal:  Nanomaterials (Basel)       Date:  2020-12-11       Impact factor: 5.076

2.  Identifying diverse metal oxide nanomaterials with lethal effects on embryonic zebrafish using machine learning.

Authors:  Richard Liam Marchese Robinson; Haralambos Sarimveis; Philip Doganis; Xiaodong Jia; Marianna Kotzabasaki; Christiana Gousiadou; Stacey Lynn Harper; Terry Wilkins
Journal:  Beilstein J Nanotechnol       Date:  2021-11-29       Impact factor: 3.649

Review 3.  Experimental and Computational Nanotoxicology-Complementary Approaches for Nanomaterial Hazard Assessment.

Authors:  Valérie Forest
Journal:  Nanomaterials (Basel)       Date:  2022-04-14       Impact factor: 5.719

4.  Evaluating the cytotoxicity of a large pool of metal oxide nanoparticles to Escherichia coli: Mechanistic understanding through In Vitro and In Silico studies.

Authors:  Supratik Kar; Kavitha Pathakoti; Paul B Tchounwou; Danuta Leszczynska; Jerzy Leszczynski
Journal:  Chemosphere       Date:  2020-09-25       Impact factor: 7.086

Review 5.  The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.

Authors:  Thelvia I Ramos; Carlos A Villacis-Aguirre; Katherine V López-Aguilar; Leandro Santiago Padilla; Claudia Altamirano; Jorge R Toledo; Nelson Santiago Vispo
Journal:  Pharmaceutics       Date:  2022-01-21       Impact factor: 6.321

Review 6.  NanoSolveIT Project: Driving nanoinformatics research to develop innovative and integrated tools for in silico nanosafety assessment.

Authors:  Antreas Afantitis; Georgia Melagraki; Panagiotis Isigonis; Andreas Tsoumanis; Dimitra Danai Varsou; Eugenia Valsami-Jones; Anastasios Papadiamantis; Laura-Jayne A Ellis; Haralambos Sarimveis; Philip Doganis; Pantelis Karatzas; Periklis Tsiros; Irene Liampa; Vladimir Lobaskin; Dario Greco; Angela Serra; Pia Anneli Sofia Kinaret; Laura Aliisa Saarimäki; Roland Grafström; Pekka Kohonen; Penny Nymark; Egon Willighagen; Tomasz Puzyn; Anna Rybinska-Fryca; Alexander Lyubartsev; Keld Alstrup Jensen; Jan Gerit Brandenburg; Stephen Lofts; Claus Svendsen; Samuel Harrison; Dieter Maier; Kaido Tamm; Jaak Jänes; Lauri Sikk; Maria Dusinska; Eleonora Longhin; Elise Rundén-Pran; Espen Mariussen; Naouale El Yamani; Wolfgang Unger; Jörg Radnik; Alexander Tropsha; Yoram Cohen; Jerzy Leszczynski; Christine Ogilvie Hendren; Mark Wiesner; David Winkler; Noriyuki Suzuki; Tae Hyun Yoon; Jang-Sik Choi; Natasha Sanabria; Mary Gulumian; Iseult Lynch
Journal:  Comput Struct Biotechnol J       Date:  2020-03-07       Impact factor: 7.271

Review 7.  Current hurdles to the translation of nanomedicines from bench to the clinic.

Authors:  Snežana Đorđević; María Medel Gonzalez; Inmaculada Conejos-Sánchez; Barbara Carreira; Sabina Pozzi; Rita C Acúrcio; Ronit Satchi-Fainaro; Helena F Florindo; María J Vicent
Journal:  Drug Deliv Transl Res       Date:  2021-07-23       Impact factor: 4.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.